Lionnard et al. found that TRIM28 binds to BCL2A1 on the mitochondria and promotes its ubiquitination degradation, thereby upregulating the sensitivity of melanoma cells to BRAF-targeted therapy (Lionnard et al., 2019). Here, BCL2A1 is linked to melanoma.